Search

Your search keyword '"Wu, Zhouliang"' showing total 136 results
Start Over Author "Wu, Zhouliang"
136 results on '"Wu, Zhouliang"'

2. Phase 2 Study of Preoperative Tislelizumab in Combination with Low-dose Nab-Paclitaxel in Patients with Muscle-invasive Bladder Cancer

Author

Wu, Zhouliang, Zhao, Gangjian, Zhang, Zhe, Shen, Chong, Wang, Lili, Xu, Guoping, Zhao, Yang, Liang, Rui, Li, Changping, Liu, Huanhuan, Wang, Hongmei, Dong, Hua, Fu, Huaying, Li, Man, Li, Hongjun, Zhuang, Yan, Da, La, Huang, Shiwang, Jia, Kaipeng, Chen, Houyuan, Bai, Yiduo, Guo, Shizheng, Cheng, Huanqing, Wang, Huina, Wang, Haitao, Niu, Yuanjie, and Hu, Hailong

Published
2025
Full Text
View/download PDF

11. Development and validation of a glycolysis-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer.

Author

Shen, Chong, Suo, Yong, Guo, Jian, Su, Wei, Zhang, Zhe, Yang, Shaobo, Wu, Zhouliang, Fan, Zhenqian, Zhou, Xiaoliang, and Hu, Hailong

Subjects
GENE expression, EPITHELIAL-mesenchymal transition, CANCER genes, CANCER cell growth, IMMUNE checkpoint inhibitors
Abstract

Background: Bladder cancer (BCa) is one of the most common malignancies worldwide, and its prognostication and treatment remains challenging. The fast growth of various cancer cells requires reprogramming of its energy metabolism using aerobic glycolysis as a major energy source. However, the prognostic and therapeutic value of glycolysis-related genes in BCa remains to be determined. Methods: The fused merge dateset from TCGA, GSE13507 and GSE31684 were used for the analysis of glycolysis-related genes expression or subtyping; and corresponding clinical data of these BCa patients were also collected. In the merge cohort, we constructed a 18 multigene signature using the least absolute shrinkage and selection operator (LASSO) Cox regression model. The four external cohorts (i.e., IMvigor210, GSE32894, GSE48276 and GSE48075) of BCa patients were used to validate the accuracy. We evaluated immune infiltration using seven published algorithms: CIBERSORT, QUANTISEQ, XCELL, TIMER, CIBERSORT-ABS, EPIC, and MCPCOUNTER. Subsequently, in order to analyze the correlation between risk groups(scores) and overall survival, recognised immunoregolatory cells or common chemotherapeutic agents, clinicopathological data and immune checkpoint-related genes of BCa patients, Wilcox rank test, chi-square test, cox regression and spearman's correlation were performed. Results: Conspicuously, we could see that CD8+ T, cancer associated fibroblast, macrophage M2, NK, endothelial cells and so on were significantly dysregulated between the two risk groups. In addition, compared with the low-risk group, high-risk group predicted poor prognosis and relatively weak sensitivity of chemotherapy. Additionally, we also found that the expression level of partial genes in the model was significantly correlated with objective responses to anti-PD-1 or anti-PD-L1 treatment in the IMvigor210, GSE111636, GSE176307, GSE78220 or GSE67501 cohort; and its expression level was also varied in different objective response cases receiving tislelizumab combined with low-dose nab-paclitaxel therapy based on our mRNA sequencing (TRUCE-01). According to "GSEA" algorithm of R package "clusterProfiler", the most significantly enriched HALLMARK, KEGG pathway and GO term was separately the 'Epithelial Mesenchymal Transition', 'Ecm Receptor Interaction' and 'MF_Extracellular_matrix_structural_constitunet' in the high- vs. low-risk group. Subsequently, we verified the protein and mRNA expression of interested model-related genes from the Human Protein Atlas (HPA) and 10 paired BCa tissues collected by us. Furthermore, in vitro functional experiments demonstrated that FASN was a functional oncogene in BCa cells through promoting cell proliferation, migration, and invasion abilities. Conclusion: In summary, the glycolysis-associated gene signature established by us exhibited a high predictive performance for the prognosis, immunotherapeutic responsiveness, and chemotherapeutic sensitivity of BCa. And, The model also might function as a chemotherapy and immune checkpoint inhibitor (ICI) treatment guidance. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

15. The prognostic significance and immune characteristics of bone morphogenetic proteins (BMPs) family: A pan-cancer multi-omics analysis.

Author

Chen, Changsheng, Zhang, Yu, Lin, Yuda, Shen, Chong, Zhang, Zhe, Wu, Zhouliang, Qie, Yunkai, Zhao, Gangjian, and Hu, Hailong

Subjects
BONE morphogenetic proteins, GENE expression, SOMATIC mutation, REVERSE transcriptase polymerase chain reaction, IMMUNE checkpoint proteins
Abstract

BACKGROUND: Bone morphogenetic proteins (BMPs) are a group of cancer-related proteins vital for development and progression of certain cancer types. Nevertheless, function of BMP family in pan-cancer was not detailedly researched. OBJECTIVE: Investigating expression pattern and prognostic value of the BMPs family (BMP1-8A and BMP8B) expression across multiple cancer types. METHODS: Our research integrated multi-omics data for exploring potential associations between BMPs expression and prognosis, clinicopathological characteristics, copy number or somatic mutations, immune characteristics, tumor microenvironment (TME), tumor mutation burden (TMB), microsatellite instability (MSI), immune checkpoint genes and drug sensitivity in The Cancer Genome Atlas (TCGA) tumors. Furthermore, association of BMPs expression and immunotherapy effectiveness was investigated in some confirmatory cohorts (GSE111636, GSE78220, GSE67501, GSE176307, IMvigor210 and mRNA sequencing data from currently undergoing TRUCE01 clinical research included), and biological function and potential signaling pathways of BMPs in bladder cancer (BCa) was explored via Gene Set Enrichment Analysis (GSEA). Eventually, immune infiltration analysis was done via BMPs expression, copy number or somatic mutations in BCa, as well as validation of the expression levels by reverse transcription-quantitative PCR and western blot, and in vitro functional experiments of BMP8A. RESULTS: Discoveries displayed BMPs expression was related to prognosis, clinicopathological characteristics, mutations, TME, TMB, MSI and immune checkpoint genes of TCGA tumors. Anticancer drug sensitivity analysis displayed BMPs were associated with various drug sensitivities. What's more, it was discovered that expression level of certain BMP family members related to objective response to immunotherapy. By GSEA, we discovered multiple immune-associated functions and pathways were enriched. Immune infiltration analysis on BCa also displayed significant associations among BMPs copy number variations, mutation status and infiltration level of diverse immune cells. Furthermore, differential expression validation and in vitro phenotypic experiment indicated that BMP8A significantly promoted BCa cell proliferation, migration and invasion. CONCLUSIONS: Current results confirmed significance of both BMPs expression and genomic alteration in the prognosis and treatment of diverse cancer types, and suggested that BMPs may be vital for BCa and can possibly be utilized as biomarkers for immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Targeted Inhibition of Lymphovascular Invasion Formation with CREKA Peptide-Modified Silicasomes to Boost Chemotherapy in Bladder Cancer

Author

Wu, Zhouliang, Li, Bozhao, Qie, Yunkai, Wu, Suying, Qi, Feilong, Chu, Tianjiao, Nie, Guangjun, and Hu, Hailong

Abstract

Despite its significant clinical efficacy as a first-line treatment for advanced bladder cancer, cisplatin-based chemotherapy provides a limited benefit for patients with lymphovascular invasion (LVI), which is characterized by the presence of tumor emboli within blood vessels and associated with enhanced cisplatin resistance and metastatic potential. Notably, platelets, a critical component of LVI, hinder the delivery of chemotherapeutic agents to tumors and facilitate metastasis. Consequently, platelet function inhibition holds the potential to disrupt LVI formation, as well as augment the antitumor activity of cisplatin. Herein, we developed a tumor microenvironment-targeted nanodrug with lipid-coated mesoporous silica nanoparticles (silicasomes) that synergistically combines cisplatin with an antiplatelet agent, tirofiban, for bladder cancer treatment. The customized nanodrug can concurrently prevent LVI formation and enhance the chemotherapeutic efficacy without significant adverse effects. This study supports the integration of chemotherapy and antiplatelet therapy via a silicasome-based nanosystem as a highly promising strategy for bladder cancer management.

Published
2024
Full Text
View/download PDF

18. Withdrawal notice to: “Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data” [Heliyon 9, (2023) 16897]

Author

Shen, Chong, primary, Fu, Chong, additional, Suo, Yong, additional, Li, Kai, additional, Zhang, Zhe, additional, Yang, Shaobo, additional, Zhang, Yu, additional, Lin, Yuda, additional, Li, Zhi, additional, Wu, Zhouliang, additional, Huang, Shiwang, additional, Chen, Houyuan, additional, Fan, Zhenqian, additional, and Hu, Hailong, additional

Published
2023
Full Text
View/download PDF

19. Development and validation of a exosome-related gene signature for predicting prognosis, immune infiltration and immunotherapeutic response in bladder cancer

Author

Shen, Chong, primary, Han, Jingwen, additional, Zhou, Xiaoliang, additional, Zhang, Yu, additional, Zhang, Zhe, additional, Liu, Yuejiao, additional, Qie, Yunkai, additional, Wu, Zhouliang, additional, Peng, Fei, additional, Chen, Changsheng, additional, Fan, ZhenQian, additional, and Hu, Hailong, additional

Published
2023
Full Text
View/download PDF

21. Comprehensive characterization of endoplasmic reticulum stress in bladder cancer revealing the association with tumor immune microenvironment and prognosis

Author

Lin, Yuda, primary, Li, Tengfei, additional, Li, Zhuolun, additional, Shen, Chong, additional, Wu, Zhouliang, additional, Zhang, Zhe, additional, Li, Zhi, additional, Yang, Shaobo, additional, Wang, Zejin, additional, Li, Peng, additional, Fu, Chong, additional, Guo, Jian, additional, and Hu, Hailong, additional

Published
2023
Full Text
View/download PDF

22. Enhancing urinary tract infection diagnosis for negative culture patients with metagenomic next-generation sequencing (mNGS)

Author

Jia, Kaipeng, primary, Huang, Shiwang, additional, Shen, Chong, additional, Li, Hongjun, additional, Zhang, Zhe, additional, Wang, Lei, additional, Zhao, Gangjian, additional, Wu, Zhouliang, additional, Lin, Yuda, additional, Xia, Han, additional, Tang, Mingze, additional, Yang, Huifen, additional, and Hu, Hailong, additional

Published
2023
Full Text
View/download PDF

25. Identification of a dysregulated CircRNA-associated gene signature for predicting prognosis, immune landscape, and drug candidates in bladder cancer

Author

Shen, Chong, primary, Li, Zhi, additional, Zhang, Yinglang, additional, Zhang, Zhe, additional, Wu, Zhouliang, additional, Da, La, additional, Yang, Shaobo, additional, Wang, Zejin, additional, Zhang, Yu, additional, Qie, Yunkai, additional, Zhao, Gangjian, additional, Lin, Yuda, additional, Huang, Shiwang, additional, Zhou, Mingli, additional, and Hu, Hailong, additional

Published
2022
Full Text
View/download PDF

31. Clinical utility of urine tumor DNA in bladder cancer patients.

Author

Hu, Hailong, primary, Niu, Yuanjie, additional, Wang, HaiTao, additional, Guo, Zhaoxia, additional, Liu, Huanhuan, additional, Shen, Chong, additional, Da, La, additional, Zhao, Gangjian, additional, Wang, Lili, additional, Wu, Zhouliang, additional, Zhang, Zhe, additional, Cao, Shanbo, additional, Lou, Feng, additional, and Wang, Huina, additional

Published
2022
Full Text
View/download PDF

34. Reducing Postoperative Recurrence of Early‐Stage Hepatocellular Carcinoma by a Wound‐Targeted Nanodrug

Author

li, Bozhao, primary, Zhang, Xiuping, additional, Wu, Zhouliang, additional, Chu, Tianjiao, additional, Yang, Zhenlin, additional, Xu, Shuai, additional, Wu, Suying, additional, Qie, Yunkai, additional, Lu, Zefang, additional, Qi, Feilong, additional, Hu, Minggen, additional, Zhao, Guodong, additional, Wei, Jingyan, additional, Zhao, Yuliang, additional, Nie, Guangjun, additional, Meng, Huan, additional, Liu, Rong, additional, and Li, Suping, additional

Published
2022
Full Text
View/download PDF

35. PD10-07 UPDATE OF TRUCE-01: NEOADJUVANT TISLELIZUMAB COMBINED WITH NAB-PACLITAXEL FOR MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA

Author

Hu, Hailong, primary, Niu, Yuanjie, additional, Wang, Haitao, additional, Shen, Chong, additional, Zhao, Gangjian, additional, Da, La, additional, Wang, Lili, additional, Wu, Zhouliang, additional, Li, Zhi, additional, Chen, Houyuan, additional, Zhan, Xuejian, additional, Jiang, Zhan, additional, and Zhang, Zhe, additional

Published
2022
Full Text
View/download PDF

36. MP59-19 UPDATE OF TRUCE-02: AN OPEN LABEL, SINGLE-ARM, PHASE 2 STUDY OF TILELIZUMAB COMBINED WITH NAB-PACLITAXEL FOR HIGH-RISK NON-MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA (HR-NMIBC) WHICH IS NOT COMPLETELY RESECTABLE

Author

Hu, Hailong, primary, Niu, Yuanjie, additional, Wang, Haitao, additional, Shen, Chong, additional, Da, La, additional, Zhao, Gangjian, additional, Wang, Lili, additional, Wu, Zhouliang, additional, Zhang, Zhe, additional, Li, Zhi, additional, Jiang, Zhan, additional, Zhan, Xuejian, additional, and Yang, Shaobo, additional

Published
2022
Full Text
View/download PDF

37. LncRNA MNX-AS1 combined with YBX1 to promote bladder cancer proliferation, migration, and invasion through activiting Wnt signaling pathway

Author

Dawei Tian, Wu Zhouliang, La Da, Songlin Zuo, Hu Hailong, Gangjian Zhao, and Chong Shen

Subjects
Bladder cancer, Cancer research, Wnt signaling pathway, medicine, Biology, medicine.disease
Abstract

Long non-coding RNAs (lncRNAs) govern fundamental biochemical and cellular processes. Bladder cancer is one of the most common genitourinary malignancies, and its proliferation, migration and invasion also regulated by many functional lncRNAs. In our study, we found that lncRNA MNX1-AS1 was highly-expressed in bladder cancer tissues and cell lines. Moreover, higher MNX1-AS1 expression was correlated with poor survival of MNX1-AS1 patients. Mechanistically, we showed that MNX1-AS1 could interact with YBX1 and promotes its location at the promoter region of β-catenin, then to promote transcriptional activation of β-catenin. In addition, MNX1-AS1/YBX1 could promote bladder cancer cells proliferation, migration and invasion through active Wnt/β-catenin signaling by induce β-catenin transcriptional activation. Consistently, we find a new functional lncRNA MNX1-AS1 can regulate bladder cancer cells proliferation, migration and invasion by target β-catenin transcriptional activation together with YBX1.

Published
2021
Full Text
View/download PDF

43. Preoperative hemoglobin-platelet ratio can significantly predict progression and mortality outcomes in patients with T1G3 bladder cancer undergoing transurethral resection of bladder tumor

Author

Tang, Gang, primary, Zhen, Yunpeng, additional, Xie, Wanqin, additional, Wang, Yinlei, additional, Chen, Feiran, additional, Qin, Chuan, additional, Yang, Han, additional, Du, Zhiyong, additional, Shen, Zhonghua, additional, Zhang, Bo, additional, Wu, Zhouliang, additional, Tian, Dawei, additional, and Hu, Hailong, additional

Published
2018
Full Text
View/download PDF

45. Impact of squamous and/or glandular differentiation on recurrence and progression following transurethral resection for non-muscle invasive urothelial carcinoma of bladder

Author

Xu, Hao, primary, Xie, Linguo, additional, Liu, Xiaoteng, additional, Zhang, Yu, additional, Shen, Zhonghua, additional, Chen, Tao, additional, Qiu, Xiaoyu, additional, Sha, Nan, additional, Xing, Chen, additional, Wu, Zhouliang, additional, Hu, Hailong, additional, and Wu, Changli, additional

Published
2017
Full Text
View/download PDF

46. The evaluation of the association between the metabolic syndrome and tumor grade and stage of bladder cancer in a Chinese population

Author

Sha,Nan, Xu,Hao, Chen,Tao, Tian,Da-Wei, Xie,Wan-Qin, Xie,Linguo, Zhang,Yu, Xing,Chen, Liu,Xiao-Teng, Shen,Zhong-Hua, Wu,Zhouliang, Hu,Hai-Long, Wu,Changli, Sha,Nan, Xu,Hao, Chen,Tao, Tian,Da-Wei, Xie,Wan-Qin, Xie,Linguo, Zhang,Yu, Xing,Chen, Liu,Xiao-Teng, Shen,Zhong-Hua, Wu,Zhouliang, Hu,Hai-Long, and Wu,Changli

Abstract

Nan Sha,1,2,* Hao Xu,1,2,* Tao Chen,1,2,* Da-wei Tian,1,2 Wan-qin Xie,3 Lin-Guo Xie,1,2 Yu Zhang,1,2 Chen Xing,1,2 Xiao-teng Liu,1,2 Zhong-Hua Shen,1,2 Zhou-Liang Wu,1,2 Hai-Long Hu1,2 Chang-Li Wu1,2 1Department of Urology, The Second Hospital of Tianjin Medical University, 2Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, Tianjin, 3Key Laboratory of Genetics and Birth Health of Hunan province, Family Planning Research Institute of Hunan Province, Changsha, Hunan, People’s Republic of China *These authors contributed equally to this work Objective: The objective of this article was to summarize the relationship between some components of metabolic syndrome (MetS) and the histopathologic findings in bladder cancer in a Chinese population. Methods: We retrospectively analyzed data of 323 patients from the Department of Urology, Second Hospital of Tianjin Medical University between January 2012 and January 2014. All the patients were diagnosed with bladder cancer for the first time. Age, height, weight, histologic stage, grade, the presence of hypertension, diabetes mellitus, and body mass index were evaluated. The 2009 American Joint Committee on Cancer TNM staging system was used, with Ta and T1 tumors accepted as lower stage and T2, T3, and T4 tumors as higher stage bladder cancers. Also, pathologists assigned tumor grade according to the 1973 World Health Organization grading system. Noninvasive papillary urothelial neoplasms of low malignant potential were regarded as low grade. Analyses were completed using chi-square tests and logistic regression analysis. Results: Of the 323 patients, 164 had hypertension, 151 had diabetes mellitus, and 213 had a body mass index ≥25 kg/m2. MetS was significantly associated with histologic grade (P<0.001) and stage (P=0.006) of bladder cancer. Adjusted for age in binary logistic regression analysis, the presence of MetS predicts the risk of higher T stage (odds ratio =4.029, P&amp

Published
2016

47. Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective study

Author

Zhang,Yu, Xie,Linguo, Chen,Tao, Xie,Wanqin, Wu,Zhouliang, Xu,Hao, Xing,Chen, Sha,Nan, Shen,Zhonghua, Qie,Yungkai, Liu,Xiao-Teng, Hu,Hailong, Wu,Changli, Zhang,Yu, Xie,Linguo, Chen,Tao, Xie,Wanqin, Wu,Zhouliang, Xu,Hao, Xing,Chen, Sha,Nan, Shen,Zhonghua, Qie,Yungkai, Liu,Xiao-Teng, Hu,Hailong, and Wu,Changli

Abstract

Yu Zhang,1,* Linguo Xie,1,* Tao Chen,1,* Wanqin Xie,2 Zhouliang Wu,1 Hao Xu,1 Chen Xing,1 Nan Sha,1 Zhonghua Shen,1 Yunkai Qie,1 Xiaoteng Liu,1 Hailong Hu,1 Changli Wu1 1Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, 2Key Laboratory of Genetics and Birth Health of Hunan Province, The Family Planning Research Institute of Hunan Province, Changsha, People’s Republic of China *These authors contributed equally to this work Objective: The management of stage 1 and grade 3 (T1G3) bladder cancer continues to be controversial. Although the transurethral resection of bladder tumor (TURBT) followed by intravesical chemotherapy is a conservative strategy for treatment of T1G3 bladder cancer, a relatively high risk of tumor recurrence and progression remains regarding the therapy. This study aimed to compare the efficacy of intravenous chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone for T1G3 bladder cancer after TURBT surgery. Methods: We retrospectively reviewed the cases of 457 patients who were newly diagnosed with T1G3 bladder urothelial carcinoma between January 2009 and March 2014. After TURBT, 281 patients received intravesical chemotherapy alone, whereas 176 patients underwent intravesical chemotherapy in combination with intravenous chemotherapy. Tumor recurrence and progression were monitored periodically by urine cytology and cystoscopy in follow-up. Recurrence-free survival and progression-free survival of the two chemotherapy strategies following TURBT were analyzed. Univariable and multivariable Cox hazards analyses were performed to predict the prognostic factors for tumor recurrence and progression. Results: The tumor recurrence rate was 36.7% for patients who received intravesical chemotherapy alone after TURBT, compared with 19.9% for patients who received intravenous chemotherapy combined with intravesical chemotherapy after TURBT (P&lt

Published
2016

50. Phase 2 Study of Preoperative Tislelizumab in Combination with Low-dose Nab-Paclitaxel in Patients with Muscle-invasive Bladder Cancer

Author

Wu, Zhouliang, Zhao, Gangjian, Zhang, Zhe, Shen, Chong, Wang, Lili, Xu, Guoping, Zhao, Yang, Liang, Rui, Li, Changping, Liu, Huanhuan, Wang, Hongmei, Dong, Hua, Fu, Huaying, Li, Man, Li, Hongjun, Zhuang, Yan, Da, La, Huang, Shiwang, Jia, Kaipeng, Chen, Houyuan, Bai, Yiduo, Guo, Shizheng, Cheng, Huanqing, Wang, Huina, Wang, Haitao, Niu, Yuanjie, and Hu, Hailong

Abstract

[Display omitted]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results